David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cost of Care

The ASCO Post Staff

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mar

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Neoadjuvant Sacituzumab Govitecan Plus Perioperative Pembrolizumab in Muscle-Invasive Bladder Cancer

Prostate Cancer Does Taking ARPIs and Anticoagulants Together Raise Risks

FDA Releases Updated Guidance on Biosimilar Development

SABCS 2025: High-Level Review of Select Data

Addition of Axitinib to Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors